{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:44:19Z","timestamp":1785527059974,"version":"3.56.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s11060-026-05677-2","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T08:37:34Z","timestamp":1782463054000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Survival outcomes and a prognostic nomogram in EGFR-mutant non-small cell lung cancer with leptomeningeal metastasis: a real-world cohort study"],"prefix":"10.1007","volume":"178","author":[{"given":"Yaping","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongqi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongzhu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingqi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1129-6308","authenticated-orcid":false,"given":"Yunjian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6444-8280","authenticated-orcid":false,"given":"Jinhuo","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"issue":"5","key":"5677_CR1","doi-asserted-by":"publisher","first-page":"101624","DOI":"10.1016\/j.esmoop.2023.101624","volume":"8","author":"EL Rhun","year":"2023","unstructured":"Rhun EL, Weller M, van den BM, Brandsma D, Furtner J, Rud\u00e0 R, Schadendorf D, Seoane J, Tonn J-C, Wesseling P, Wick W, Minniti G, Peters S, Curigliano G, Preusser M (2023) Leptomeningeal metastasis from solid tumours: EANO\u2013ESMO clinical practice guideline for diagnosis, treatment and follow-up. ESMO Open 8(5):101624. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101624.","journal-title":"ESMO Open"},{"key":"5677_CR2","doi-asserted-by":"publisher","unstructured":"Cheng H, Perez-Soler R (2018) Leptomeningeal metastases in non-small-cell lung cancer. The Lancet Oncol 19(1):e43\u2013e55. https:\/\/doi.org\/10.1016\/S1470-2045(17)30689-7.","DOI":"10.1016\/S1470-2045(17)30689-7"},{"key":"5677_CR3","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ctrv.2016.12.006","volume":"53","author":"J Remon","year":"2017","unstructured":"Remon J, Le Rhun E, Besse B (2017) Leptomeningeal carcinomatosis in non-small cell lung cancer patients: a continuing challenge in the personalized treatment era. Cancer Treat Rev 53:128\u2013137. https:\/\/doi.org\/10.1016\/j.ctrv.2016.12.006.","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"5677_CR4","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1097\/JTO.0000000000000669","volume":"10","author":"BC Liao","year":"2015","unstructured":"Liao BC, Lee JH, Lin CC, Chen Y-F, Chang C-H, Ho C-C, Shih J-Y, Yu C-J, Yang JC-H (2015) Epidermal growth factor receptor tyrosine kinase inhibitors for non\u2013small-Cell lung cancer patients with Leptomeningeal Carcinomatosis. J Thorac Oncol 10(12):1754\u20131761. https:\/\/doi.org\/10.1097\/JTO.0000000000000669.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"5677_CR5","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.jtho.2019.12.113","volume":"15","author":"MJ Ahn","year":"2020","unstructured":"Ahn MJ, Chiu CH, Cheng Y, Han J-Y, Goldberg SB, Greystoke A, Crawford J, Zhao Y, Huang X, Johnson M, Vishwanathan K, Yates JWT, Brown AP, Mendoza-Naranjo A, Mok T (2020) Osimertinib for patients with leptomeningeal metastases associated with EGFR T790M-Positive Advanced NSCLC: the AURA leptomeningeal metastases analysis. J Thorac Oncol 15(4):637\u2013648. https:\/\/doi.org\/10.1016\/j.jtho.2019.12.113.","journal-title":"J Thorac Oncol"},{"key":"5677_CR6","doi-asserted-by":"publisher","unstructured":"Grommes C, Oxnard GR, Kris MG, Miller VA, Pao W, Holodny AI, Clarke JL, Lassman AB (2011) \u201cPulsatile\u201d high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro-Oncology 13(12):1364\u20131369. https:\/\/doi.org\/10.1093\/neuonc\/nor121.","DOI":"10.1093\/neuonc\/nor121"},{"issue":"6","key":"5677_CR7","doi-asserted-by":"publisher","first-page":"4527","DOI":"10.18632\/oncotarget.2886","volume":"6","author":"DM Jackman","year":"2015","unstructured":"Jackman DM, Cioffredi LA, Jacobs L, Sharmeen F, Morse LK, Lucca J, Plotkin SR, Marcoux PJ, Rabin MS, Lynch TJ, Johnson BE, Kesari S (2015) A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer. Oncotarget 6(6):4527\u20134536. https:\/\/doi.org\/10.18632\/oncotarget.2886.","journal-title":"Oncotarget"},{"issue":"11","key":"5677_CR8","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/j.jtho.2016.06.029","volume":"11","author":"YS Li","year":"2016","unstructured":"Li YS, Jiang BY, Yang JJ, Tu H-Y, Zhou Q, Guo W-B, Yan H-H, Wu Y-L (2016) Leptomeningeal metastases in patients with NSCLC with EGFR mutations. J Thorac Oncol 11(11):1962\u20131969. https:\/\/doi.org\/10.1016\/j.jtho.2016.06.029.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"5677_CR9","doi-asserted-by":"publisher","first-page":"101594","DOI":"10.1016\/j.esmoop.2023.101594","volume":"8","author":"K Tamura","year":"2023","unstructured":"Tamura K, Yoshida T, Masuda K, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Ohe Y (2023) Comparison of clinical outcomes of osimertinib and first-generation EGFR-tyrosine kinase inhibitors (TKIs) in TKI-untreated EGFR-mutated non-small-cell lung cancer with leptomeningeal metastases. ESMO Open 8(4):101594. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101594.","journal-title":"ESMO Open"},{"issue":"6","key":"5677_CR10","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1200\/JCO.19.00457","volume":"38","author":"JCH Yang","year":"2020","unstructured":"Yang JCH, Kim SW, Kim DW, Lee J-S, Cho BC, Ahn J-S, Lee DH, Kim TM, Goldman JW, Natale RB, Brown AP, Collins B, Chmielecki J, Vishwanathan K, Mendoza-Naranjo A, Ahn M-J (2020) Osimertinib in patients with Epidermal growth factor receptor mutation\u2013positive non\u2013small-Cell lung cancer and leptomeningeal metastases: the BLOOM study. JCO 38(6):538\u2013547. https:\/\/doi.org\/10.1200\/JCO.19.00457.","journal-title":"JCO"},{"key":"5677_CR11","doi-asserted-by":"publisher","unstructured":"Park S, Baldry R, Jung HA et al. Phase II Efficacy and safety of 80 mg osimertinib in patients with leptomeningeal metastases associated with Epidermal growth factor receptor mutation-positive non-small cell lung cancer (BLOSSOM). J Clin Oncol. Published online June 3, 2024: JCO2400708. doi: https:\/\/doi.org\/10.1200\/JCO.24.00708.","DOI":"10.1200\/JCO.24.00708"},{"issue":"1","key":"5677_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1158\/1078-0432.CCR-22-1585","volume":"29","author":"G Ozcan","year":"2023","unstructured":"Ozcan G, Singh M, Vredenburgh JJ (2023) Leptomeningeal metastasis from non\u2013small cell lung cancer and Current landscape of treatments. Clin Cancer Res 29(1):11\u201329. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1585.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"5677_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jtho.2024.09.1385","volume":"20","author":"H Chen","year":"2025","unstructured":"Chen H, Yang S, Wang L, Wu Y, Wu Y, Ma S, He Z, Zhang C, Liu Y, Tang H, Dong H, Wang Q (2025) High-dose furmonertinib in patients with EGFR-Mutated NSCLC and leptomeningeal metastases: a prospective real-world study. J Thorac Oncol 20(1):65\u201375. https:\/\/doi.org\/10.1016\/j.jtho.2024.09.1385.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"5677_CR14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12885-025-15503-z","volume":"26","author":"K Jin","year":"2025","unstructured":"Jin K, Qu Y, Li S, Sun C, Wang L (2025) A survival prediction model for leptomeningeal metastasis patients with non-small cell lung cancer based on deep learning. BMC Cancer 26(1):175. https:\/\/doi.org\/10.1186\/s12885-025-15503-z.","journal-title":"BMC Cancer"},{"issue":"4","key":"5677_CR15","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cllc.2024.02.001","volume":"25","author":"Y Wu","year":"2024","unstructured":"Wu Y, Zhao Y, Wu Y, Chen H, Ma S, Wang Q (2024) A retrospective real-world study of prognostic factors associated with EGFR mutated lung cancer with leptomeningeal metastasis. Clin Lung Cancer 25(4):347\u2013353.e1. https:\/\/doi.org\/10.1016\/j.cllc.2024.02.001.","journal-title":"Clin Lung Cancer"},{"issue":"3","key":"5677_CR16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/jjco\/hyae162","volume":"55","author":"N Jirattikanwong","year":"2025","unstructured":"Jirattikanwong N, Charoentum C, Phenphinan N, Pooriwarangkakul P, Ruttanaphol D, Phinyo P (2025) Individual survival prediction model for patients with leptomeningeal metastasis. Jpn J Clin Oncol 55(3):237\u2013245. https:\/\/doi.org\/10.1093\/jjco\/hyae162.","journal-title":"Jpn J Clin Oncol"},{"issue":"7","key":"5677_CR17","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/neuonc\/noaa298","volume":"23","author":"E Le Rhun","year":"2021","unstructured":"Le Rhun E, Devos P, Weller J, Seystahl K, Mo F, Compter A, Berghoff AS, Jongen JLM, Wolpert F, Rud\u00e0 R, Brandsma D, van den Bent M, Preusser M, Herrlinger U, Weller M (2021) Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors. Neuro-Oncology 23(7):1100\u20131112. https:\/\/doi.org\/10.1093\/neuonc\/noaa298.","journal-title":"Neuro-Oncology"},{"issue":"2","key":"5677_CR18","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s11060-025-04938-w","volume":"172","author":"L Zhuang","year":"2025","unstructured":"Zhuang L, Yin X, Liu X, Liu D, Wei Z, Chen Y, Zhao K, Li Y, Yu J, Meng X (2025) Efficacy and safety of aumolertinib in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis: a single\u2011center retrospective study. J Neurooncol 172(2):461\u2013470. https:\/\/doi.org\/10.1007\/s11060-025-04938-w.","journal-title":"J Neurooncol"},{"key":"5677_CR19","doi-asserted-by":"publisher","first-page":"175883592514033","DOI":"10.1177\/17588359251403396","volume":"17","author":"W Yun","year":"2025","unstructured":"Yun W, Liu A, Wen J, Zhao K, Meng X (2025) Treatment options for EGFR mutation-positive NSCLC patients with leptomeningeal metastases after third-generation TKI resistance: a retrospective real-world study. Ther Adv Med Oncol 17:17588359251403396. https:\/\/doi.org\/10.1177\/17588359251403396.","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"5677_CR20","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13014-019-1376-z","volume":"14","author":"W Yan","year":"2019","unstructured":"Yan W, Liu Y, Li J, Han A, Kong L, Yu J, Zhu H (2019) Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis. Radiat Oncol 14(1):168. https:\/\/doi.org\/10.1186\/s13014-019-1376-z.","journal-title":"Radiat Oncol"},{"issue":"1","key":"5677_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s13014-020-01627-y","volume":"15","author":"J Zhen","year":"2020","unstructured":"Zhen J, Wen L, Lai M, Zhou Z, Shan C, Li S, Lin T, Wu J, Wang W, Xu S, Liu D, Lu M, Zhu D, Chen L, Cai L, Zhou C (2020) Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study. Radiat Oncol 15(1):185. https:\/\/doi.org\/10.1186\/s13014-020-01627-y.","journal-title":"Radiat Oncol"},{"issue":"3","key":"5677_CR22","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s11060-024-04616-3","volume":"167","author":"K Nakagawa","year":"2024","unstructured":"Nakagawa K, Takano K, Nishino K, Ohe S, Nakayama T, Arita H (2024) Prognostic impact of clinical and radiological factors on leptomeningeal metastasis from solid cancers. J Neurooncol 167(3):397\u2013406. https:\/\/doi.org\/10.1007\/s11060-024-04616-3.","journal-title":"J Neurooncol"},{"issue":"2","key":"5677_CR23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s11060-025-05059-0","volume":"174","author":"Q Xie","year":"2025","unstructured":"Xie Q, Hu J, Liu Y, Tabengwa GT, Huang J, Liu S, Chen P, Hu Q, Zhang X, Xie T (2025) Retrospective study of leptomeningeal metastasis: unveiling the indolent and rapid progression phases. J Neurooncol 174(2):357\u2013368. https:\/\/doi.org\/10.1007\/s11060-025-05059-0.","journal-title":"J Neurooncol"},{"key":"5677_CR24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejca.2015.12.021","volume":"56","author":"JW Hyun","year":"2016","unstructured":"Hyun JW, Jeong IH, Joung A, Cho HJ, Kim SH, Kim HJ (2016) Leptomeningeal metastasis: clinical experience of 519 cases. Eur J Criminol Cancer 56:107\u2013114. https:\/\/doi.org\/10.1016\/j.ejca.2015.12.021.","journal-title":"Eur J Criminol Cancer"},{"key":"5677_CR25","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.lungcan.2019.03.015","volume":"131","author":"K Yin","year":"2019","unstructured":"Yin K, Li YS, Zheng MM, Jiang B-Y, Li W-F, Yang J-J, Tu H-Y, Zhou Q, Zhong W-Z, Yang X-N, Chen H-J, Yan H-H, Li L-L, Wu Y-L, Zhang X-C (2019) A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases. Lung Cancer 131:134\u2013138. https:\/\/doi.org\/10.1016\/j.lungcan.2019.03.015.","journal-title":"Lung Cancer"},{"issue":"6","key":"5677_CR26","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1111\/tbj.13433","volume":"25","author":"T Znidaric","year":"2019","unstructured":"Znidaric T, Gugic J, Marinko T, Gojkovic Horvat A, Paulin Kosir MS, Golo D, Ivanetic Pantar M, Ratosa I (2019) Breast cancer patients with brain metastases or leptomeningeal disease: 10-year results of a national cohort with validation of prognostic indexes. The Breast J 25(6):1117\u20131125. https:\/\/doi.org\/10.1111\/tbj.13433.","journal-title":"The Breast J"},{"issue":"1","key":"5677_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-26131-z","volume":"12","author":"Q Li","year":"2022","unstructured":"Li Q, Lin Z, Hong Y, Fu Y, Chen Y, Liu T, Zheng Y, Tian J, Liu C, Pu W, Ding Z, Wang C (2022) Brain parenchymal and leptomeningeal metastasis in non-small cell lung cancer. Sci Rep 12(1):1. https:\/\/doi.org\/10.1038\/s41598-022-26131-z.","journal-title":"Sci Rep"},{"key":"5677_CR28","doi-asserted-by":"publisher","unstructured":"Yang C, Cai H, Liu W et al. (2025 November 25) Cerebrospinal fluid metabolomics and machine learning identify novel biomarkers for lung cancer leptomeningeal metastasis. Neuro Oncol. Published online noaf270. https:\/\/doi.org\/10.1093\/neuonc\/noaf270.","DOI":"10.1093\/neuonc\/noaf270"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05677-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05677-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05677-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:08:22Z","timestamp":1785521302000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05677-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["5677"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05677-2","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"6 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Fujian Provincial Cancer Hospital (Fuzhou, China).","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"80"}}